Amid a reckoning for the gene therapy field, Vertex Pharmaceuticals has joined a growing list of companies paring back their research efforts around the adeno-associated virus (AAV) vectors used ...

In a groundbreaking advancement for families grappling with the challenges of Dravet syndrome, a rare and life-altering form of epilepsy, scientists have developed a new gene replacement therapy ...

Danish start-up Fuse Vectors has received $5.2 million in preseed financing to further develop their gene therapy technology. The company has developed a cell-free platform for producing adeno ...

Today, Fuse Vectors announces $5.2 million in pre-seed financing led by HCVC to revolutionize gene therapy development with its cell-free viral vector technology. The funding will accelerate the ...

Copenhagen, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Gene therapy's biggest obstacle isn't science - it's manufacturing. While the field races forward with breakthrough treatments, production remains stuck ...

Today, Fuse Vectors announces $5.2 million in pre-seed financing led by HCVC to revolutionize gene therapy development with its cell-free viral vector technology .